ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: PO2117

Pegloticase for Uncontrolled Gout in Kidney Transplant Recipients: Provisional Data Report of a Multicenter, Open-Label, Efficacy and Safety Study

Session Information

Category: Transplantation

  • 1902 Transplantation: Clinical


  • Abdellatif, Abdul A., Baylor College of Medicine, Houston, Texas, United States
  • Zhao, Lin, Horizon Therapeutics plc, Deerfield, Illinois, United States
  • Peloso, Paul M., Horizon Therapeutics plc, Deerfield, Illinois, United States
  • Cherny, Katya, Horizon Therapeutics plc, Deerfield, Illinois, United States
  • Marder, Brad, Horizon Therapeutics plc, Deerfield, Illinois, United States
  • Scandling, John D., Stanford University School of Medicine, Stanford, California, United States
  • Saag, Kenneth G., University of Alabama at Birmingham, Birmingham, Alabama, United States

Kidney transplant (KT) recipients have a high prevalence and severity of gout. Pegloticase (pegylated recombinant uricase) rapidly metabolizes urate and efficacy is not impacted by CKD stage. Immunomodulator co-therapy with pegloticase has improved treatment response rates over phase 3 monotherapy trials by attenuating anti-drug antibodies (ADAs). This ongoing Phase 4 trial (PROTECT NCT04087720) examines safety and efficacy of pegloticase in KT patients with uncontrolled gout (UCG).


KT recipients with UCG (serum urate [SU]≥7 mg/dL, intolerance/inefficacy to urate lowering therapy, and ≥1 of the following: tophi, chronic gouty arthritis, ≥2 flares in past yr) and functioning KT graft (eGFR≥15 ml/min/1.73m2) on stable immunosuppressive (IMS) therapy are included (KT>1 y earlier). Pegloticase (8mg q2w for 24wks) safety and efficacy are examined. Primary endpoint was SU responders during Month 6 (SU <6 mg/dL for ≥80% of time). Health Assessment Questionnaire (HAQ) pain (most severe: 100) and Disability Index (HAQ-DI) scores (max: 3) were evaluated.


20 patients enrolled (mean±SD; age: 53.9±10.9 y, time since KT: 14.7±6.9 y, SU: 9.4±1.5 mg/dL, gout duration: 8.4±11.6 y; all on ≥2 IMS). At the time of analysis, 10 patients completed treatment, 3 discontinued study, 2 met SU monitoring rules (pre-dose SU>6 mg/dL at 2 consecutive visits) and discontinued pegloticase, and 5 were ongoing. All patients experienced initial substantial reductions in SU, which was maintained in the majority; 2 patients met monitoring rules. At week 24, no notable eGFR changes were observed. In patients that completed treatment, HAQ-pain and HAQ-DI scores improved by 26.7±30.3 (baseline: 35.9±30.2) and 0.2±0.5 (baseline: 1.0±1.0), respectively, at Week 24 (n=10). 7 SAEs (2 cellulitis, duodenal ulcer, sepsis, a-fib, diverticulitis, and localized infection) deemed unrelated to pegloticase, were reported in 5 patients. No anaphylaxis or IR events have occurred.


Preliminary results from the PROTECT trial, with Fall 2021 completion, demonstrate substantial and sustained SU decrease in the majority of KT recipients with uncontrolled gout. These findings are consistent with other reports on the effect of immunomodulation use with pegloticase.


  • Commercial Support